Proprietary method of producing CRM197 will be used to develop affordable vaccines for children and adults in developing nations
ROCKVILLE, Md.–(BUSINESS WIRE)–Fina Biosolutions announces that the United States Patent and Trademark Office has issued a patent for expression and purification of the conjugate vaccine protein CRM197 in E. coli. CRM197 is a key component of many vaccine formulations utilized worldwide.
“Our goal is to reduce the vaccine cost barrier and grant people in need access to life-saving vaccines,” said Dr. Andrew Lees, Founder and CEO of Fina Biosolutions. “We couldn’t be more pleased to announce that we succeeded in creating a needed vaccine protein, CRM197, in an efficient and more cost-effective way. Our proprietary method of production will help people around the world protect themselves, their children and their loved ones from pneumonia, meningitis and more.”